Articles Vol. 66 No. 1 07/01/2025

48. ASSESSMENT OF THE FLUCTUATION OF ANTI-SARS – COV-2 IGG TITLE AND RELATED FACTORS IN COVID- 19 PATIENTS

Dang Duc Hoan1,2, Do Manh Thang1,2
1 Son Tay General Hospital
2 Bệnh viện Đa khoa Sơn Tây
Corresponding author: drdang9806@gmail.com
DOI: 10.52163/yhc.v66i1.1953
18 Views
17 Downloads
Keywords
Covid-19 anti-SARS CoV-2 IgG disease types Son Tay General Hospital
Abstract

Objective: To determine the change in anti-SARS-CoV-2 IgG concentration in CoVid-19 patients in Hanoi and to study the factors related to anti-SARS-CoV-2 IgG concentration in the above subjects.

Subjects and methods: Cross-sectional descriptive study at 4 time points: T0 (While being treated at the Central Tropical Hospital: 271 patients); T6 (After 6 months of infection: 250 patients); T12 (After 12 months of infection: 250 patients) and T18 (After 18 months of infection: 270 patients).

Results: Regarding age: group T0 has the highest average age: 55.5±16.4 (4 - 90); In terms of gender: women account for the majority in groups T6; T12 and T18, while men in group T0 are more numerous, accounting for 59.4%. BMI of the 4 stages are similar, mainly classified as normal (18 - 25); In terms of underlying diseases: Group T0 has the highest rate of underlying diseases, accounting for 60.89%, while T6 is 25.2%; group T12 is 22%; group T18 is 21.9%; In terms of vaccination history: Group T0 has received the least 32.1% of vaccinations; In terms of disease severity: Group T0 has the highest rate of severe and critical: 43.5% and 28.8%. Antibody concentration of group T0: 494.55 UI/ml (106.43- 1119.17); T6: 355.58 UI/ml
(241.95- 507.13); T12: 173.62 UI/ml (133.01- 229.47); T18: 74.9 UI/ml (53.13- 106.17).

Conclusion: Correlation was found between disease types and anti-SARS CoV-2 antibody concentration in group T0. Anti-SARS CoV-2 antibody concentration decreased over time but still existed up to 18 months after infection.

References
[1]
Z. Xu, L. Shi, Y. Wang và cộng sự (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 8 (4), 420-422. Google Scholar
[2]
WHO (2003). Tình hình dịch COVID-19 trên thế giới và khuyến nghị của Tổ chức Y tế thế giới. https://vncdc.gov.vn/tinh-hinh-dich-covid-19-tren-the-gioi-va-khuyen-nghi-cua-to-chuc-yte-the-gioi-who-nd17305.html, Google Scholar
[3]
M. I. de Oliveira, M. R. Aciole, P. A. F. Neves và cộng sự (2024). A stronger antibody response in increased disease severity of SARS-CoV-2. BMC Infectious Diseases, 24 (1), 17. Google Scholar
[4]
S. Prato, M. E. Paladino, M. A. Riva và cộng sự (2021). COVID-19 Vaccination and Asymptomatic Infection: Effect of BNT162b2 mRNA Vaccine on the Incidence of COVID-19 and Duration of Sick Leave Among Healthcare Workers. Journal of occupational and environmental medicine, 63 (12), e868-e870. Google Scholar
[5]
S. Hoshida, N. Koeda, H. Hattori và cộng sự (2022). Age- and sex-based changes in spike protein antibody status after SARS-CoV-2 vaccination and effect of past-infection in healthcare workers in Osaka. BMC Infect Dis, 22 (1), 709. Google Scholar
[6]
R. Varnai, T. Molnar, L. Zavori và cộng sự (2022). Serum Level of Anti-Nucleocapsid, but Not Anti-Spike Antibody, Is Associated with Improvement of Long COVID Symptoms. Vaccines, 10 (2), 165. Google Scholar
[7]
T. B. Onyango, F. Zhou, G. Bredholt và cộng sự (2023). SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients. Front Immunol, 14, 1287388. Google Scholar
[8]
D.-Y. Lin, F. Abi Fadel, S. Huang và cộng sự Google Scholar
[9]
(2023). Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections. JAMA Network Open, 6 (9), e2335077-e2335077. Google Scholar
[10]
S. L. S. Penetra, H. F. P. Santos, P. C. Resende và cộng sự (2023). SARS-CoV-2 Reinfection Cases in a Household-Based Prospective Cohort in Rio de Janeiro. J Infect Dis, 228 (12), 1680-1689. Google Scholar